APTINYX INC.

APTX NASDAQ
3.220
-0.050
-1.53%
After Hours: 3.220 0 0.00% 17:00 08/16 EDT
Open
3.310
Prev Close
3.270
High
3.310
Low
3.160
Volume
98.58K
Avg Vol (3M)
231.07K
52 Week High
32.25
52 Week Low
2.880
% Turnover
0.31%
Market Cap
101.33M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers APTINYX INC. APTX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.
MORE >

Recently

Name
Price
%Change